FDA Updates Orange Book: Generic Drugs Still Mostly Equal
Published Date: 8/24/2026
Notice
Summary
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Orange Book TE Evaluations Aid Cost Containment
The FDA finalized guidance explaining therapeutic equivalence evaluations and therapeutic equivalence (TE) codes that are listed in the Active section of the Orange Book for multisource prescription drug products approved under the FD&C Act. The guidance says these TE evaluations are public information for state health agencies, prescribers, and pharmacists to promote public education and to "foster containment of health care costs." The guidance availability is announced August 24, 2026.
New Process for 505(b)(2) Applicants to Request TE Codes
The final guidance includes revisions that reflect an additional process by which applicants of certain 505(b)(2) applications may request therapeutic equivalence (TE) codes. This change is part of the finalized guidance announced August 24, 2026, and relates specifically to applicants of 505(b)(2) drug applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
Previous / Next Documents
Previous: 2026-17213, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Revisions to the U.S. Geological Survey's Bird Banding and Marking Permit Application
In accordance with the Paperwork Reduction Act (PRA) of 1995, the U.S. Geological Survey (USGS) is proposing to renew an information collection with revisions.
Next: 2026-17216, Notice of Availability and Request for Comments on Draft Navigation and Vessel Inspection Circular 02-99 Change 1-Guidance on the Streamlined Inspection Program
The Coast Guard announces the availability of draft Navigation and Vessel Inspection Circular (NVIC) 02-99, Change 1, Guidance on the Streamlined Inspection Program. NVIC 02-99, Change 1 would modernize the program guidance to reflect industry advancements in digital recordkeeping, maintenance management systems, and third-party auditing. This update would emphasize a risk-based verification model that reduces redundant physical inspections, broadens acceptable compliance formats, and provides updated procedures for deficiency management and temporary hull repairs.